Andrew Booth, Chief Financial Officer of AbCellera Biologics Inc., filed a Form 4 on November 13, 2026, disclosing an open-market purchase of 8,600 common shares on that same date.

Key Highlights

  • Reporting person: Andrew Booth, identified as Chief Financial Officer of AbCellera Biologics Inc. (NASDAQ:ABCL)
  • Transaction: Purchase (Code P) of 8,600 common shares on November 13, 2026
  • Price paid: $11.33 per share
  • Direct holdings after transaction: 491,400 common shares held directly
  • Indirect holdings: 130,959 common shares held indirectly by spouse
  • No derivative securities were reported as acquired, disposed of, or beneficially owned in this filing

Andrew Booth's November 2026 Share Purchase at AbCellera Biologics

According to the Form 4 filing, Andrew Booth, the Chief Financial Officer of AbCellera Biologics Inc. (NASDAQ:ABCL), acquired 8,600 common shares on November 13, 2026, at a price of $11.33 per share. The transaction was coded "P," indicating an open-market purchase. The filing was signed by Tryn Stimart as attorney-in-fact on the same date.

Following the reported transaction, the filing discloses that Booth directly holds 491,400 common shares. In addition, the filing reports 130,959 common shares held indirectly by his spouse. No transactions in derivative securities, such as options or warrants, were reported in Table II of the filing.

The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox on the form was not marked. The filing covers a single transaction with a date of earliest transaction of November 13, 2026, and was submitted as an individual filing by one reporting person.

What Was Disclosed

AbCellera Biologics CFO Andrew Booth reported a purchase of 8,600 common shares at $11.33 each on November 13, 2026, bringing his direct beneficial ownership to 491,400 shares, with an additional 130,959 shares held indirectly by his spouse.